248 related articles for article (PubMed ID: 22769724)
21. Stem cell models for drug discovery and toxicology studies.
Liu W; Deng Y; Liu Y; Gong W; Deng W
J Biochem Mol Toxicol; 2013 Jan; 27(1):17-27. PubMed ID: 23293059
[TBL] [Abstract][Full Text] [Related]
22. Preclinical predictors of clinical safety: opportunities for improvement.
Sistare FD; DeGeorge JJ
Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
[TBL] [Abstract][Full Text] [Related]
23. Drug development and nonclinical to clinical translational databases: past and current efforts.
Monticello TM
Toxicol Pathol; 2015 Jan; 43(1):57-61. PubMed ID: 25389276
[TBL] [Abstract][Full Text] [Related]
24. Using high-content screening technology for studying drug-induced hepatotoxicity in preclinical studies.
Donato MT; Gómez-Lechón MJ; Tolosa L
Expert Opin Drug Discov; 2017 Feb; 12(2):201-211. PubMed ID: 27936962
[TBL] [Abstract][Full Text] [Related]
25. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
26. Incidence and nature of testicular toxicity findings in pharmaceutical development.
Sasaki JC; Chapin RE; Hall DG; Breslin W; Moffit J; Saldutti L; Enright B; Seger M; Jarvi K; Hixon M; Mitchard T; Kim JH
Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):511-25. PubMed ID: 22162370
[TBL] [Abstract][Full Text] [Related]
27. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
28. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
[TBL] [Abstract][Full Text] [Related]
29. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
[TBL] [Abstract][Full Text] [Related]
30. Regulatory acceptance of animal models of disease to support clinical trials of medicines and advanced therapy medicinal products.
Cavagnaro J; Silva Lima B
Eur J Pharmacol; 2015 Jul; 759():51-62. PubMed ID: 25814257
[TBL] [Abstract][Full Text] [Related]
31. Quantitative knowledge-based analysis in compound safety assessment.
Bureeva S; Nikolsky Y
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):287-98. PubMed ID: 21254873
[TBL] [Abstract][Full Text] [Related]
32. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
[TBL] [Abstract][Full Text] [Related]
33. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development.
Whitebread S; Hamon J; Bojanic D; Urban L
Drug Discov Today; 2005 Nov; 10(21):1421-33. PubMed ID: 16243262
[TBL] [Abstract][Full Text] [Related]
34. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
35. Neuroimaging of pain: advances and future prospects.
Stephenson DT; Arneric SP
J Pain; 2008 Jul; 9(7):567-79. PubMed ID: 18455479
[TBL] [Abstract][Full Text] [Related]
36. Juvenile animal toxicity study designs to support pediatric drug development.
Cappon GD; Bailey GP; Buschmann J; Feuston MH; Fisher JE; Hew KW; Hoberman AM; Ooshima Y; Stump DG; Hurtt ME
Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047
[TBL] [Abstract][Full Text] [Related]
37. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
[TBL] [Abstract][Full Text] [Related]
38. Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment.
Trosko JE; Chang CC
Toxicology; 2010 Mar; 270(1):18-34. PubMed ID: 19948204
[TBL] [Abstract][Full Text] [Related]
39. Proceedings of the Second Workshop on Theory meets Industry (Erwin-Schrödinger-Institute (ESI), Vienna, Austria, 12-14 June 2007).
Hafner J
J Phys Condens Matter; 2008 Feb; 20(6):060301. PubMed ID: 21693862
[TBL] [Abstract][Full Text] [Related]
40. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
Sistare FD; DeGeorge JJ
Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
